Therapeutics: Mammalian target of rapamycin complex 1 (mTORC1) inhibition; AKT1 substrate 1 proline-rich (AKT1S1)

In vitro and mouse studies suggest genetically controlled, transient mTORC1 inhibition in engineered T cells could help treat cancer. In mouse T cells, transduction with an inducible expression vector...